Shim Ji Sung, Choi Hoon, Noh Tae Il, Tae Jong Hyun, Yoon Sung Goo, Kang Seok Ho, Bae Jae Hyun, Park Hong Seok, Park Jae Young
Department of Urology, Korea University Ansan Hospital, Ansan, Korea.
Department of Urology, Korea University Anam Hospital, Seoul, Korea.
Korean J Urol. 2015 Jun;56(6):429-34. doi: 10.4111/kju.2015.56.6.429. Epub 2015 May 28.
This study was designed to estimate the value of a second transurethral resection of bladder tumor (TURBT) procedure in patients with initially diagnosed T1 high-grade bladder cancer.
Between August 2009 and January 2013, a total of 29 patients with T1 high-grade bladder cancer prospectively underwent a second TURBT procedure. Evaluation included the presence of previously undetected residual tumor, changes to histopathological staging or grading, and tumor location. Recurrence-free and progression-free survival curves were generated to compare the prognosis between the groups with and without residual lesions by use of the Kaplan-Meier method.
Of 29 patients, 22 patients (75.9%) had residual disease after the second TURBT. Staging was as follows: no tumor, 7 (24.1%); Ta, 5 (17.2%); T1, 6 (20.7%); Tis, 6 (20.7%); Ta+Tis, 1 (3.4%); T1+Tis, 1 (3.4%); and ≥T2, 3 (10.3%). The muscle layer was included in the surgical specimen after the initial TURBT in 24 patients (82.7%). In three patients whose cancer was upstaged to pT2 after the second TURBT, the initial surgical specimen contained the muscle layer. In the group with residual lesions, the 3-year recurrence-free survival and 3-year progression-free survival rates were 50% and 66.9%, respectively, whereas these rates were 68.6% and 68.6%, respectively, in the group without residual lesions. This difference was not statistically significant.
Initial TURBT does not seem to be enough to control T1 high-grade bladder cancer. Therefore, a routine second TURBT procedure should be recommended in patients with T1 high-grade bladder cancer to accomplish adequate tumor resection and to identify patients who may need to undergo prompt cystectomy.
本研究旨在评估初次诊断为T1期高级别膀胱癌患者行二次经尿道膀胱肿瘤切除术(TURBT)的价值。
2009年8月至2013年1月,共有29例T1期高级别膀胱癌患者前瞻性地接受了二次TURBT手术。评估内容包括是否存在先前未检测到的残留肿瘤、组织病理学分期或分级的变化以及肿瘤位置。采用Kaplan-Meier法绘制无复发生存曲线和无进展生存曲线,以比较有无残留病变组之间的预后情况。
29例患者中,22例(75.9%)在二次TURBT后有残留病灶。分期情况如下:无肿瘤,7例(24.1%);Ta期,5例(17.2%);T1期,6例(20.7%);Tis期,6例(20.7%);Ta+Tis期,1例(3.4%);T1+Tis期,1例(3.4%);≥T2期,3例(10.3%)。24例(82.7%)患者初次TURBT后的手术标本包含肌层。在3例二次TURBT后癌症分期升为pT2期的患者中,初次手术标本包含肌层。在有残留病变的组中,3年无复发生存率和3年无进展生存率分别为50%和66.9%,而在无残留病变的组中,这些比率分别为68.6%和68.6%。这种差异无统计学意义。
初次TURBT似乎不足以控制T1期高级别膀胱癌。因此,对于T1期高级别膀胱癌患者,应建议常规行二次TURBT手术,以实现充分的肿瘤切除,并识别可能需要立即行膀胱切除术的患者。